Dr. Jaume Reventós, head of the Research Unit in Biomedicine and Translational and Pediatric Oncology at Vall d'Hebron Research Institute (VHIR), was the speaker of a Plenary Conference in the Centennial Congress of the Catalan Society of Biology with the title 'High-throughput biomedical transcriptomics and proteomics: their relevance in our health system'.This is the summary of the conference: "Major investments in high-throughput techniques, such as transcriptomics and proteomics, have created an opportunity for significant progress in biomedical research and especially in cancer. During the last years, researchers have identified hundreds of genes and proteins that harbor variations contributing to cancer development and also can serve as biomarkers for screening, diagnosis and prognosis. Moreover, the recent improvement of sensitivity and dynamic range for those techniques, has led to the possibility for the analysis of complex biological samples, such as body fluids (blood, urine, etc.), which allow to the non invasive methods for the detection of the diseases. Our main aim is to improve the early detection of hormo-dependent cancers, including prostate (PC), endometrial (EC) and ovarian cancer (OC). For all those cancers, poor sensitivity, failure rate and invasiveness of the current diagnosis methods limit the success to early detect them and consequently advanced disease is often encountered. We have analyzed urine (for PC), uterine aspirates (for EC) and ascites (for OC) by using high-throughput techniques to pursue our goal. Our data demonstrated that both, transcriptomic and proteomic approaches are able to reveal novel biomarkers for these cancers. This constitutes an important step towards advancing accurate non-invasive diagnosis and prognosis, which currently represents a setback in our ability to cure patients".